INS and Hypoglycemia: By contrast, the continuous intravenous infusion of glibenclamide to patients with large hemispheric ischemic infarctions provided a constant therapeutic dose of the agent without spikes in serum drug levels leading to insulin release and resultant hypoglycemia [33].